# Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/low-dose-ipilimumab-in-combination-with-nivolumab-or-pembrolizumab-for-the/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Tara Cowling,Heather K. Neilson,Ransi Nayakarathna,Quenby Mahood |
| Citations | 0 |
| DOI | 10.51731/cjht.2022.405 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | diamond |
| OA URL | https://canjhealthtechnol.ca/index.php/cjht/article/download/RC1441/RC1441 |
| OpenAlex ID | https://openalex.org/W4288490070 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Ransi Nayakarathna](https://scholariq.org/researchers/ransi-nayakarathna/)

## Paper journal

- [Canadian Journal of Health Technologies](https://scholariq.org/journals/canadian-journal-of-health-technologies/)

## Paper primary topic

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Paper topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.